<DOC>
	<DOCNO>NCT00520299</DOCNO>
	<brief_summary>The purpose study test new drug call ADI-SS PEG 20,000 mw patient melanoma . The study drug ( ADI-SS PEG 20,000 mw ) use cause nutrient call arginine break . Arginine amino acid . Amino acid building block body use make protein . Normal cell require arginine . Melanoma cell , however , seem need arginine survive . ADI-SS PEG 20,000 mw use way starve melanoma cell stop grow .</brief_summary>
	<brief_title>Phase I/II Study ADI-SS PEG 20,000mw Patients With Advanced Metastatic Melanoma</brief_title>
	<detailed_description>This phase I/II , open-label , dose-escalation study ADI-SS PEG 20,000 mw patient advance melanoma . Eligible patient receive ADI-SS PEG 20,000 mw intramuscularly ( IM ) weekly 9 week ( Cycle 1 ) . [ 18F ] -FDG PET CT scan perform baseline end cycle 1 ( week 8 9 respectively ) assessment tumor response change tumor metabolic activity induce ADI-SS PEG 20,000 mw . [ 18F ] -FDG PET also perform study day 4 assessment tumor metabolic activity follow first dose ADI-SS PEG 20,000 mw . Formal assessment response RECIST EORTC functional criterion base comparison conventional CT scan [ 18F ] -FDG PET scan do pre-treatment end Cycle 1 ( week 8 9 ) . Blood sample obtain prior ADI-SS PEG 20,000 mw IM injection plasma arginine citrulline level ADI concentration analysis detection anti-ADI antibody . Patients assess physical examination laboratory study ( CBC , fibrinogen , PT/PTT , comprehensive chemistry panel , LDH , amylase , lipase uric acid ) every two week undergoing treatment . A review toxicity conduct study visit . If patient completes treatment Cycle 1 without Dose limit toxicity ( DLT , patient eligible continue Cycle 2 start study week # 10 one follow criterion meet : 1 . CT show enlargement exist disease without accompany symptom . 2 . CT show stable disease improvement unacceptable toxicity . If patient develops symptom referable disease progression CT show new disease , ADI give . Radiologic evaluation repeat patient treated Cycle 2 study week 16 17 determine eligibility Cycle 3 . The eligibility criterion use Cycle 2 apply continuation Cycle 3 . Phase I : The dose level ADI-SS PEG 20,000mw administer outline : - Cohort 1 ( 40 IU/m2 ) - Cohort 2 ( 80 IU/m2 ) - Cohort 3 ( 160 IU/m2 ) Phase II : The cohort determine high tolerate dose level Phase I expand 25 patient .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Skin Neoplasms</mesh_term>
	<criteria>1 . Patients must histologically confirm malignant melanoma , AJCC stage III ( unresectable ) IV . Patients uveal mucosal melanoma eligible . 2 . Measurable disease use RECIST criterion ( Appendix 1 ) . 3 . For patient , pathology slide must review Memorial Hospital Department Pathology NYU Department Pathology confirmation melanoma diagnosis . 4 . Patients must Karnofsky performance status least 80 . 5 . Patients must adequate organ marrow function define : WBC &gt; 3,000/microL absolute neutrophil count &gt; 1,500/microL platelet &gt; 100,000/microL total bilirubin &lt; 2.5X upper normal institutional limit LDH &lt; 1.5 X upper normal institutional limit albumin &gt; 3.0 mg/dl creatinine &lt; 2.0 mg/dl 6 . Expected survival least 3 month . 7 . Age â‰¥ 18 year . 8 . Able willing give valid write informed consent . 1 . Patients chemotherapy , immunotherapy radiotherapy within 3 week prior first dose study agent recover adverse event due agent administer 3 week earlier . For nitrosoureas , last six week must elapse . 2 . Any malignancy require concomitant therapy . 3 . Any medical condition might make difficult patient complete full course treatment ground exclusion , discretion Principal Investigator coPrincipal Investigators . 4 . Metastatic disease central nervous system , unless treat stable . 5 . Known HIV positivity . 6 . Mental impairment may compromise ability give informed consent comply requirement study . 7 . Lack availability clinical followup assessment . 8 . Participation clinical trial involve another investigational agent within 3 week prior enrollment . 9 . Pregnant woman woman nurse eligible . Women childbearing potential sexually active men must use appropriate contraception course study . Women childbearing potential must pregnant ( negative beta HCG within 2 week treatment ) nursing treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>metastatic melanoma</keyword>
	<keyword>ADI</keyword>
	<keyword>ADI PEG 20</keyword>
	<keyword>ADI SS PEG 20,000mw</keyword>
	<keyword>arginine</keyword>
	<keyword>enzyme therapy</keyword>
</DOC>